The University of Southampton
University of Southampton Institutional Repository

Change in tau phosphorylation associated with neurodegeneration in the ME7 model of prion disease

Change in tau phosphorylation associated with neurodegeneration in the ME7 model of prion disease
Change in tau phosphorylation associated with neurodegeneration in the ME7 model of prion disease
Hyperphosphorylation of the microtubule-associated protein tau is a significant determinant in AD (Alzheimer's disease), where it is associated with disrupted axonal transport and probably causes synaptic dysfunction. Although less well studied, hyperphosphorylation has been observed in prion disease. We have investigated the expression of hyperphosphorylated tau in the hippocampus of mice infected with the ME7 prion agent. In ME7-infected animals, there is a selective loss of CA1 synapse, first discernable at 13 weeks of disease. There is a potential that dysfunctional axonal transport contributes to this synaptopathy. Thus investigating hyperphosphorylated tau that is dysfunctional in AD could illuminate whether and how they are significant in prion disease. We observed no differences in the levels of phosphorylated tau (using MC1, PHF-1 and CP13 antibodies) in detergent-soluble and detergent-insoluble fractions extracted from ME7- and NBH- (normal brain homogenate) treated animals across disease. In contrast, we observed an increase in phospho-tau staining for several epitopes using immunohistochemistry in ME7-infected hippocampal sections. Although the changes were not of the magnitude seen in AD tissue, clear differences for several phospho-tau species were seen in the CA1 and CA3 of ME7-treated animals (pSer(199-202)>pSer(214)>PHF-1 antibody). Temporally, these changes were restricted to animals at 20 weeks and none of the disease-related staining was associated with the axons or dendrites that hold CA1 synapses. These findings suggest that phosphorylation of tau at the epitopes examined does not underpin the early synaptic dysfunction. These data suggest that the changes in tau phosphorylation recorded here and observed by others relate to end-stage prion pathology when early dysfunctions have progressed to overt neuronal loss.
0300-5127
545-551
Asuni, Ayodeji A.
b1412b1b-9794-4705-aada-aed5d3da038f
Perry, V. Hugh
8f29d36a-8e1f-4082-8700-09483bbaeae4
O'Connor, Vincent
8021b06c-01a0-4925-9dde-a61c8fe278ca
Asuni, Ayodeji A.
b1412b1b-9794-4705-aada-aed5d3da038f
Perry, V. Hugh
8f29d36a-8e1f-4082-8700-09483bbaeae4
O'Connor, Vincent
8021b06c-01a0-4925-9dde-a61c8fe278ca

Asuni, Ayodeji A., Perry, V. Hugh and O'Connor, Vincent (2010) Change in tau phosphorylation associated with neurodegeneration in the ME7 model of prion disease. Biochemical Society Transactions, 38 (2), 545-551. (doi:10.1042/BST0380545). (PMID:20298219)

Record type: Article

Abstract

Hyperphosphorylation of the microtubule-associated protein tau is a significant determinant in AD (Alzheimer's disease), where it is associated with disrupted axonal transport and probably causes synaptic dysfunction. Although less well studied, hyperphosphorylation has been observed in prion disease. We have investigated the expression of hyperphosphorylated tau in the hippocampus of mice infected with the ME7 prion agent. In ME7-infected animals, there is a selective loss of CA1 synapse, first discernable at 13 weeks of disease. There is a potential that dysfunctional axonal transport contributes to this synaptopathy. Thus investigating hyperphosphorylated tau that is dysfunctional in AD could illuminate whether and how they are significant in prion disease. We observed no differences in the levels of phosphorylated tau (using MC1, PHF-1 and CP13 antibodies) in detergent-soluble and detergent-insoluble fractions extracted from ME7- and NBH- (normal brain homogenate) treated animals across disease. In contrast, we observed an increase in phospho-tau staining for several epitopes using immunohistochemistry in ME7-infected hippocampal sections. Although the changes were not of the magnitude seen in AD tissue, clear differences for several phospho-tau species were seen in the CA1 and CA3 of ME7-treated animals (pSer(199-202)>pSer(214)>PHF-1 antibody). Temporally, these changes were restricted to animals at 20 weeks and none of the disease-related staining was associated with the axons or dendrites that hold CA1 synapses. These findings suggest that phosphorylation of tau at the epitopes examined does not underpin the early synaptic dysfunction. These data suggest that the changes in tau phosphorylation recorded here and observed by others relate to end-stage prion pathology when early dysfunctions have progressed to overt neuronal loss.

Text
Asuni_0380545.pdf - Version of Record
Download (760kB)

More information

Published date: April 2010

Identifiers

Local EPrints ID: 180209
URI: http://eprints.soton.ac.uk/id/eprint/180209
ISSN: 0300-5127
PURE UUID: 3776a55c-3d23-40f5-9e9c-c02e8d6fe171
ORCID for Vincent O'Connor: ORCID iD orcid.org/0000-0003-3185-5709

Catalogue record

Date deposited: 06 Apr 2011 10:44
Last modified: 15 Mar 2024 03:04

Export record

Altmetrics

Contributors

Author: Ayodeji A. Asuni
Author: V. Hugh Perry

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×